Arax Advisory Partners’s Tvardi Therapeutics TVRD Stock Holding History

Arax Advisory Partners’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.9K	Buy	11,003 +2,670	+32%	+$8.37K	﹤0.01%	3931
2026 Q1	$26.5K	Sell	8,333 -67	-0.8%	-$262	﹤0.01%	1968
2025 Q4	$36.1K	Buy	8,400 +6,173	+277%	+$55.3K	﹤0.01%	1790
2025 Q3	$86.8K	Buy	2,227 +1,360	+157%	+$38.7K	﹤0.01%	1585
2025 Q2	$20.2K	Sell	867 -2	-0.2%	-$47	﹤0.01%	1655
2025 Q1	$13.2K	Buy	869 +667	+330%	+$10.1K	﹤0.01%	1474
2024 Q4	$3.71K	Sell	202 -8	-4%	-$87	﹤0.01%	1842
2024 Q3	$2.33K	Hold	210	–	–	﹤0.01%	2007
2024 Q2	$1.95K	Buy	210 +8	+4%	+$191	﹤0.01%	1978
2024 Q1	$6.62K	Hold	202	–	–	﹤0.01%	853
2023 Q4	$5.41K	Hold	202	–	–	﹤0.01%	876
2023 Q3	$12.2K	Buy	202 +139	+221%	+$13K	﹤0.01%	676
2023 Q2	$6.44K	Buy	63 +41	+186%	+$5.65K	﹤0.01%	807
2023 Q1	$3.81K	Hold	22	–	–	﹤0.01%	906
2022 Q4	$8.32K	Buy	22 +1	+5%	+$380	﹤0.01%	675
2022 Q3	$7K	Hold	21	–	–	﹤0.01%	732
2022 Q2	$7K	Hold	21	–	–	﹤0.01%	713
2022 Q1	$9K	Hold	21	–	–	﹤0.01%	677
2021 Q4	$9K	Hold	21	–	–	﹤0.01%	690
2021 Q3	$12K	Buy	21 +20	+2,000%	+$10K	﹤0.01%	624
2021 Q2	$0	Buy	+1	New	+$634	﹤0.01%	937

Other funds holding TVRD

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Arax Advisory Partners's TVRD Position: Q2 2026 in Review

Arax Advisory Partners increased its Tvardi Therapeutics (TVRD) stake by 32% in Q2 2026, buying an estimated $8.37K and bringing the position to 11,003 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3931.

Arax Advisory Partners first reported a position in TVRD in Q2 2021 and has held it in 21 quarters since. The position peaked at $86.8K in Q3 2025. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

Arax Advisory Partners held 11,003 shares of Tvardi Therapeutics worth $20.9K as of Q2 2026.
Arax Advisory Partners bought 2,670 Tvardi Therapeutics shares in Q2 2026, an estimated $8.37K.
Tvardi Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3931 holding.
Arax Advisory Partners first reported a position in Tvardi Therapeutics in Q2 2021 and has held it in 21 quarters since.
Arax Advisory Partners's Tvardi Therapeutics position peaked at $86.8K in Q3 2025.
58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.